Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study

Mycobacterium avium complex (MAC) bacteria, i.e. Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium chimaera and related species, can cause severe pulmonary disease (MAC-PD), especially in patients with chronic pulmonary diseases, like COPD and bronchiectasis [1, 2].

[1]  J. Brożek,et al.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline , 2020, European Respiratory Journal.

[2]  M. Loebinger,et al.  Nontuberculous Mycobacterial Pulmonary Disease , 2015 .

[3]  J. Yim,et al.  Amikacin Liposome Inhalation Suspension for Treatment‐Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open‐Label, Randomized Study , 2018, American journal of respiratory and critical care medicine.

[4]  R. Wallace,,et al.  A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review. , 2018, International journal of systematic and evolutionary microbiology.

[5]  S. Holland,et al.  Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement , 2018, European Respiratory Journal.

[6]  W. Hoefsloot,et al.  Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort. , 2017, Respiratory medicine.

[7]  C. Ki,et al.  Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype , 2017, European Respiratory Journal.

[8]  S. Field,et al.  Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin. , 2016, Chest.

[9]  D. van Soolingen,et al.  Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin , 2015, Antimicrobial Agents and Chemotherapy.

[10]  R. Wallace,,et al.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. , 2014, Chest.

[11]  C. Daley,et al.  In Vitro Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial Disease , 2012, Antimicrobial Agents and Chemotherapy.

[12]  T. Marras,et al.  The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada , 2010, European Respiratory Journal.

[13]  S. Field,et al.  Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. , 2003, Chest.

[14]  J. Igual,et al.  Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[15]  Mikio Oka,et al.  A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. , 2007, Respiratory medicine.